Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATOP 7 is a line of topical veterinary dermatology products developed by Nextmune under the Dermoscent brand. It is specifically formulated to manage atopic dermatitis and other allergic skin conditions in companion animals, such as dogs and cats. The product line includes various formulations like spot-ons, sprays, shampoos, and mousses. Its mechanism of action involves restoring the skin barrier through the delivery of phytoceramides and essential fatty acids (Omega-3 and Omega-6), while providing anti-pruritic and anti-inflammatory effects via naturally-derived ingredients like hemp seed oil and essential oils. It is designed as a steroid-free option for sensitive, irritated, or allergy-prone skin, either as a standalone treatment for mild cases or as an adjunctive therapy for severe dermatologic conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ATOP 7.